Hester Biosciences Ltd

Hester Biosciences Ltd

  • Price (INR)0.00
  • Today's Change0.00 / --
  • Shares traded0.00
  • 1 Year change--
  • Beta1.2927
Data delayed at least 15 minutes.
More ▼

Profile data is unavailable for this security.

About the company

Hester Biosciences Limited is an India-based company engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division. It provides over 40 products across poultry vaccines (live and inactivated), large animal vaccines (live and inactivated), health products and diagnostics. Its product range includes vaccines, drugs, feed supplements and disinfectants. It manufactures over two live vaccines for large animals, including Peste des Petits Ruminants (PPR) Live vaccines and Goat Pox Vaccine. Its offerings include Avian, including Live B1, Live LAS, Live R2B, Live M48, Live FP, Gumboro M1, Gumboro I and Gumboro I+; swine fever vaccines, and large animal, including PPR Vaccine-Sungri 96 strain and Brucella abortus (S19) calf Vaccine. It offers services, such as seromonitoring for poultry farms and mastitis prevention programs for cattle farms.

  • Revenue in INR (TTM)419.71m
  • Net income in INR75.64m
  • Incorporated1987
  • Employees350.00
  • Location
  • Phone+91 7 926445107
  • Fax+91 7 926445105
  • Websitehttp://www.hesterbiosciences.co.in/
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.